在体外评估索利霉素（CEM-101）对 2009 年在美国和欧洲分离的病原体的作用。
The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009).
机构信息
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA.
出版信息
J Infect. 2010 Dec;61(6):476-83. doi: 10.1016/j.jinf.2010.08.010. Epub 2010 Sep 8.
OBJECTIVES
Solithromycin (formerly CEM-101) is a novel fluoroketolide with potent activity against bacterial pathogens that are susceptible or resistant to other MLS(B)-ketolide agents. The objective of this study was to assess the activity of solithromycin and comparator antimicrobials against a large number and variety of contemporary clinical bacterial pathogens collected in the United States (USA) and Europe during 2009.
METHOD
During 2009, a total of 10,670 non-duplicated clinical isolates were collected from 52 medical centers located in the USA (27 centers; 6228 isolates) and Europe (25 centers; 4442 isolates). Susceptibility testing and interpretation were performed using CLSI reference methods.
RESULTS
Among 1363 Streptococcus pneumoniae isolates, 99.9% of the strains displayed solithromycin MIC values at ≤0.5 mg/L, and 100% were inhibited at an MIC of 1 mg/L. Solithromycin demonstrated activity and potency against Haemophilus influenzae comparable to azithromycin (MIC(50), 1 mg/L and MIC(90), 2 mg/L) and was very potent against all 313 Moraxella catarrhalis isolated (MIC(50), 0.06 mg/L and MIC(90), 0.12 mg/L). Against 4729 Staphylococcus aureus isolates, solithromycin (MIC(50), 0.06 mg/L and MIC(90), >4 mg/L) activity was greater against methicillin-susceptible isolates (MIC(50), 0.06 mg/L and MIC(90), 0.06 mg/L) compared to methicillin-resistant isolates (MIC(50), 0.06 mg/L and MIC(90), >4 mg/L). Solithromycin was very active against all 757 β-haemolytic streptococci (MIC(50), ≤0.03 mg/L and MIC(90), 0.06 mg/L) and 310 viridans group streptococci (MIC(50), ≤0.03 mg/L and MIC(90), 0.06 mg/L) evaluated.
CONCLUSION
This contemporary surveillance study utilizing clinical isolates shows that solithromycin exhibits favorable in vitro potency and spectrum of activity against bacterial pathogens most frequently isolated in community-acquired respiratory tract (CA-RTI) and skin and skin structure infections (SSSI).
目的
索利霉素（原名 CEM-101）是一种新型氟酮内酯，对易受其他 MLS(B)-酮内酯类药物影响或耐药的细菌病原体具有强大的活性。本研究的目的是评估索利霉素和比较抗菌药物对 2009 年在美国（美国）和欧洲收集的大量不同种类的当代临床细菌病原体的活性。
方法
2009 年，从位于美国的 52 个医疗中心（27 个中心；6228 株）和欧洲（25 个中心；4442 株）共收集了 10670 株非重复的临床分离株。使用 CLSI 参考方法进行药敏试验和解释。
结果
在 1363 株肺炎链球菌分离株中，99.9%的菌株对索利霉素的 MIC 值为≤0.5 mg/L，100%的菌株在 MIC 为 1 mg/L 时被抑制。索利霉素对流感嗜血杆菌的活性和效力与阿奇霉素相当（MIC（50）为 1 mg/L，MIC（90）为 2 mg/L），对所有 313 株卡他莫拉菌的活性均非常强（MIC（50）为 0.06 mg/L，MIC（90）为 0.12 mg/L）。在 4729 株金黄色葡萄球菌分离株中，索利霉素（MIC（50）为 0.06 mg/L，MIC（90）为>4 mg/L）对甲氧西林敏感分离株（MIC（50）为 0.06 mg/L，MIC（90）为 0.06 mg/L）的活性大于对甲氧西林耐药分离株（MIC（50）为 0.06 mg/L，MIC（90）为>4 mg/L）。索利霉素对所有 757 株β-溶血性链球菌（MIC（50）为≤0.03 mg/L，MIC（90）为 0.06 mg/L）和 310 株草绿色链球菌（MIC（50）为≤0.03 mg/L，MIC（90）为 0.06 mg/L）的活性非常高。
结论
本研究采用临床分离株进行的当代监测研究表明，索利霉素对社区获得性呼吸道（CA-RTI）和皮肤及皮肤结构感染（SSSI）中最常分离的细菌病原体具有良好的体外效力和广谱活性。
Zotero 插件